Mutual of America Capital Management LLC Sells 1,104 Shares of Catalent, Inc. (NYSE:CTLT)

Mutual of America Capital Management LLC cut its position in shares of Catalent, Inc. (NYSE:CTLT) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,094 shares of the company’s stock after selling 1,104 shares during the period. Mutual of America Capital Management LLC’s holdings in Catalent were worth $1,083,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC bought a new stake in shares of Catalent in the 4th quarter valued at approximately $205,000. Tobam lifted its stake in shares of Catalent by 2.6% in the 4th quarter. Tobam now owns 338,255 shares of the company’s stock valued at $15,198,000 after purchasing an additional 8,618 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Catalent in the 4th quarter valued at approximately $6,720,000. Americana Partners LLC bought a new stake in shares of Catalent in the 4th quarter valued at approximately $2,569,000. Finally, Arizona State Retirement System lifted its stake in shares of Catalent by 0.7% in the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock valued at $2,226,000 after purchasing an additional 365 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CTLT. UBS Group reaffirmed a “neutral” rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Barclays increased their price target on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. StockNews.com began coverage on Catalent in a report on Friday. They issued a “sell” rating on the stock. Finally, Stephens reiterated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $52.46.

Catalent Trading Up 1.0 %

CTLT opened at $56.05 on Tuesday. The stock’s fifty day moving average is $56.81 and its two-hundred day moving average is $48.30. The company has a market capitalization of $10.14 billion, a P/E ratio of -8.24, a PEG ratio of 5.98 and a beta of 1.20. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $60.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 earnings per share. Analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.